Selective inhibitors of vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity

Bibliography

• BARON R, NEFF L, LOUVARD D,COURTOY PJ: Cell-mediated extracellular acidification and bone resorp-tion: evidence for a low pH in resorbing lacunae and localization of a 100 kD lysosomal membrane protein at the osteoclast ruffled border. J. Cell Biol. (1985) 101:2210–2222.
   PubMed Web of Science ®Google Scholar
• HALL TJ, CHAMBERS TJ: Molecular aspect of osteoclastfunction. Inflamm. Res. (1996) 45:1–9.
   PubMed Web of Science ®Google Scholar
• BLAIR HC, TEITELBAUM SM, GHISELLI R, GLUCK S: Osteo-clastic bone resorption by a polarized vacuolar proton pump. Science (1989) 245:855–857.
   PubMed Web of Science ®Google Scholar
• •Identification of the osteoclast proton pump as a V-ATPase.
   Google Scholar
• FINBOW EF, HARRISON MA: The vacuolar 11±-ATPase: a universal proton pump of eukaryotes. Biochem. J. (1997) 324:697–712.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review on the structure and function of V-ATPases.
   Google Scholar
• FORGAC M: Regulation of vacuolar acidification. Soc. Gen. Physic)]. Ser. (1996) 51:121–132.
   PubMedGoogle Scholar
• •Comprehensive review on the biochemistry of V-ATPases in particular on the regulation of the vacuolar acidification.
   Google Scholar
• LI YP, CHEN W, STASHENKO P: Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit. Biochem. Biophys. Res. Commun. (1996) 218:813–821.
   PubMedGoogle Scholar
• VAN HILLE B, RICHENER H, EVANS DB, GREEN JR, BILBEG: Identification of two subunit A isoforms of the vacuolar 11±-ATPase in human osteoclastoma. J. Biol. Chem. (1993) 268:7075–7080.
   PubMed Web of Science ®Google Scholar
• HERNANDO N, BARTKIEWICZ M, COLLIN-OSBODY P, OS-BODY P, BARON R: Alternative splicing generates a sec-ond isoform of the catalytic A subunit of the vacuolar 11±-ATPase. Proc. Natl. Acad. ScL USA (1995) 92:6087–6091.
   PubMedGoogle Scholar
• CHATTERJEE D, CHAKRABORTY M, LEIT Metal: Sensitiv-ity to vanadate and isoforms of subunits A and B distin-guish the osteoclast proton pump from other vacuolar ATPases. Proc. Natl. Acad. ScL USA (1992) 89:6257–6261.
   PubMed Web of Science ®Google Scholar
• VAN HILLE BV, VANEK M, RICHENER H, GREEN JR, BILBE G: Cloning and tissue distribution of subunits C, D, and E of the human vacuolar 11±-ATPase. Biochem. Biophys. Res. Commun. (1993) 197:15–21.
   PubMed Web of Science ®Google Scholar
• SCOTT BB, CHAPMAN CG: The putative 116 kDa osteo-clast specific vacuolar proton pump subunit has ubiq-uitous tissue distribution. Eur. J. Pharmacol. (1998) 346:R3–R4.
   Google Scholar
• VAN HILLE B, RICHENER H, GREEN JR, BILBE G: The ubiquitous VA68 isoform of subunit A of the vacuolar 11±-ATPase is highly expressed in human osteoclasts. Biochem. Biophys. Res. Commun. (1995) 214:1108–1113.
   PubMedGoogle Scholar
• CHATTERJEE D, NEFF L, CHAKRABORTY M, FABRICANT C, BARON R: Sensitivity to nitrate and other oxyanions further distinguishes the vanadate-sensitive osteoclast proton pump from other vacuolar ATPases. Biochemis-try (1993) 32:2808–2812.
   PubMedGoogle Scholar
• MATTSSON JP, SCHLESINGER PH, KEELING DJ et al.: Isola-tion and reconstitution of a vacuolar-type proton pump of osteoclast membranes. J. Biol. Chem. (1994) 269:24979–24982.
   PubMed Web of Science ®Google Scholar
• ••A detailed paper on purification and reconstitution of V-ATPase of c0c.
   Google Scholar
• HALL TJ, SCHAUEBLIN M: A pharmacological assessment of the mammalian osteoclast vacuolar 11±-ATPase. Bone Min. (1994) 27:159–166.
   PubMedGoogle Scholar
• LI YP, CHEN W, STASHENKO P: Molecular cloning and characterization of a putative novel human osteoclast-specific 116-kDa vacuolar proton pump subunit. Biochem. Biophys. Res. Commun. (1996) 218:813–821.
   PubMedGoogle Scholar
• YU E, CHEN W, LEES R, HEERSCHE J, MANOLSON MF:Identification of vacuolar-type proton-ATPase subunits unique to osteoclasts. Bone (1998) 23(Suppl.):S549.
   Google Scholar
• SCOTT BB, CHAPMAN CG: The putative 116 kDa osteo-clast specific vacuolar proton pump subunit has ubiq-uitous tissue distribution. Eur. J. Pharmacol (1998) 346:R3–R4.
   Google Scholar
• LAITALA T, VAANANEN HK: Proton channel part of vacuolarlitATPase and carbonic anhydrase II expres-sion is stimulated in resorbing osteoclasts. J. Bone MM. Res. (1993) 8:119–126.
   PubMed Web of Science ®Google Scholar
• LAITALA T, VAANANEN HK: Inhibition of bone resorp-tion in vitro antisense RNA and DNA molecules tar-geted against carbonic anhydrase II or two subunits of vacuolar 1-1±-ATPase. j Clin. Invest. (1994) 93:2311–2318.
   PubMed Web of Science ®Google Scholar
• BOWMANN EJ, SIEBERS A, ALTENDORF K: Bafilomycin: aclass of inhibitors of membrane ATPases from micro-organisms, animal cells, and plant cells. Proc. Natl. Acad. Sci. USA (1988) 85:7972–7976.
   PubMedGoogle Scholar
• •Identification of bafilomycin macrolides as potent and spe-cific inhibitors of V-ATPases.
   Google Scholar
• DROSE S, BINDSEIL KU, BOWMAN EJ etal.: Inhibitory ef-fect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases. Biochemistry (1993) 32:3902–3906.
   Google Scholar
• SUNDQUIST K, LAKKAKORPI P, WALLMARK B, VAANANEN K: Inhibition of osteoclast proton trans-port by bafilomycin Ai abolishes bone resorption. Bio-chem. Biophys. Res. Commun. (1990) 168:309–313.
   PubMed Web of Science ®Google Scholar
• •Proof of concept paper on involvement of osteoclast V-ATPase in bone resorption.
   Google Scholar
• FARINA C, BELFIORE P, CLARKE GD etal.: Bafilomycin At inhibits bone resorption in vivo after systemic admini-stration. J. Bone Min. Res. (1995) 10\(Supp1.1):5296.
   Google Scholar
• RYBERG B, HERSLOF, IVARSSON J et al: Bafilomycin At inhibits bone resorption in rats. J. Bone Min. Res. (1996) 11 (Suppl. 1) :S399
   Google Scholar
• KEELING DJ, HERSLOF M, MATTSSON JP, RYBERG B: Tissue-selective inhibition of vacuolar acid pumps. Acta Physiol. Scand (1998) 643:195–201.
   Google Scholar
• •Novel and simplified bafilomycin derivatives with increased selectivity and reduced toxicity.
   Google Scholar
• TRECHSEL U, STUTZER A, FLEISCH H: Hypercalcemia in-duced with an arotinoid in thyroparathyroidecto-mized rats. J. Clin. Invest. (1987) 80:1679–1686.
   PubMed Web of Science ®Google Scholar
• MATTSSON JP, HERSLOF M, RYBERG B et al: Selective in-hibition of the avian osteoclast acid pump in vitro in-creases the selectivity of bone resorption inhibition in vivo. J Bone Min. Res. (1997) 12 (Suppl. 1):S287.
   Google Scholar
• HANESSIAN S, TEHIM A, MENG Q, GRANBERG K: A re-markably facile and stereochemically controlled frag-mentation reaction in the hygrolide group of macrolide antibiotics. Tetrahedron Letts. (1996) 37:9001–9004.
   Google Scholar
• HERSLOF M, BERGMAN R, EDVINSSON K et al.: Novel bafilomycin-related acid pump inhibitors and their se-lectivity in vivo. J. Bone MM. Res. (1997) 12 (Suppl. 1):S195.
   Google Scholar
• GAGLIARDI S, GATTI PA, BELFIORE P etal. Synthesis and structure-activity relationships of bafilomycin Ai de-rivatives as inhibitors of vacuolar ATPase. J. Merl. Chem. (1998) 41:1883–1893.
   Google Scholar
• ••This paper reports the SAR of a number of bafilomycin de-rivatives and the identification of the minimal structural re-quirements for V-ATPase inhibitory activity.
   Google Scholar
• GAGLIARDI S, GATTI PA, CERRI A, FARINA C: An unusually facile preparation of 21-alkoxyderivates of bafilo-mycin At. Tetrahedron Letts. (1997) 38:479–482.
   Google Scholar
• GATTI PA, GAGLIARDI S, CERRI A et al.: Selective oxida-tion of hydroxy groups of bafilomycin Ai. J. Org. Chem. (1996) 61:7185–7188.
   PubMedGoogle Scholar
• GATTI PA, GAGLIARDI S, CERRI A, FARINA C: Novel frag-mentation reactions of bafilomycin Ai. Tetrahedron Letts. (1997) 38:6949–6952.
   Google Scholar
• GAGLIARDI S, NADLER G, CONSOLANDI E et al.: 545,6-Dichloro-2-indoly1)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar 11±-A-TPase of osteoclasts with bone antiresorptive activity. J. Merl. Chem. (1998) 41:1568–1573.
   PubMed Web of Science ®Google Scholar
• ••Synthesis and biological activity of potent and selective in-hibitors of osteoclast ATPase which also inhibits bone re-sorption by human osteoclasts.
   Google Scholar
• NADLER G, MORVAN M, DELIMOGE I et al.: (2Z,4)-5-(5,6-Dichloro-2-indoly0-2-methoxy-N-(1,2, 2,6,6-pentamethylpiperidin-4-y1)-2,4-penta- diena-mide: a novel, potent and selective inhibitor of the os-teoclast V-ATPase. Bioorg. Med. Chem. Lett. (1998) 8:3621–3626.
   PubMed Web of Science ®Google Scholar
• ••Synthesis and pharmacological characterisation ofSB-242784.
   Google Scholar
• VOTTA BJ, LEVY MA, BADGER A et al: Peptide aldehydeinhibitors of catepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Min. Res. (1997) 12:1396–1405.
   PubMed Web of Science ®Google Scholar
• DODDS RA, MINEHART H, JAMES IE etal.: In situ demon-stration of selective inhibition of the osteoclast V-ATPase using a novel inhibitor. J. Bone Min. Res. (1997) 12 (Suppl. 1):S193.
   Google Scholar
• VISENTIN L, VALENTE M, DODDS R etal.: SB-242784, a se-lective inhibitor of the osteoclast V-1-1±-ATPase, pre-vents bone loss in ovariectomized rats. Bone (1998) 23 (Suppl.):S181.
   Google Scholar
• ••This abstract shows osteoclast selectivity and anti-osteoporotic efficacy of SB-242784.
   Google Scholar
• MIZUNASHI K, FURUKAWA Y, KATANO K, ABE K: Effect of omeoprazole, an inhibitor of 1-1±,K+-ATPase, on bone resorption in humans. Calcif Tissue (1993) 53:21–25.
   PubMed Web of Science ®Google Scholar
• FABRICANT C, DAVID P, CHATTERJEE D, BARON R: The omeoprazole analog (WY 47766) is a selective inhibi-tor of vacuolar-type 1-1±-ATPases. J. Bone Min. Res. (1993) 8\(Suppl. 1):S392.
   Google Scholar
• CORBETT JW, KERR JS, WONG P et al. 2-Sulfinyl ben- zothiazoles, -oxazoles, and-imidazoles are novel in vitro bone anti-reabsorptive compounds. Med. Chem. Res. (1997) 7:151–167.
   Web of Science ®Google Scholar
• KODAYRA Y: Toxic substances to insects, produced byAspergillus ochraceus and Oospora destructor. Agric. Biol. Chem. (1961) 25:261–263.
   Google Scholar
• MUROI M, SHIRAGAMI N, TAKATSUKI A: Destruxin B, aspecific and readly reversible inhibitor of vacuolar-type Httranslocating ATPase. Biochem. Biophys. Res. Commun. (1994) 205:1358–1365.
   PubMed Web of Science ®Google Scholar
• NAGANUMA S, KUZUYA N, SAKAI K, HASUMI K, ENDO A:Inhibition of the accumulation of lipid droplets in macrophage J774 by bafilomycin Bi and destruxin E. Biochim. Biophys. Acta (1992) 1126:41–48.
   PubMedGoogle Scholar
• NORDSTROM T, GRINSTEIN S, BRISSEAU GF, MANOLSONMF, ROTSTEIN OD: Protein kinase C activation acceler-ates proton extrusion by vacuolar-type litATPase in murine peritoneal macrophages. FEBS Letts. (1994) 350:82–86.
   PubMedGoogle Scholar
• NIIKURA K, TAKANO M, TAKESHITA N et al: Inhibitionof bone resorption in vitro and in vivo by a novel in-hibitor of vacuolar ATPase, FR 167356. Bone (1998) 23(Suppl.):S549.
   Google Scholar
• •In this abstract the activity, selectivity and tolerability of a novel inhibitor with unknown structure is reported.
   Google Scholar
• BLAIR HC, TEITELBAUM LS, TAN H-L, SCHLESINGER PH:Reversible inhibition of osteoclastic activity by bone-bound gallium(110. J. Cell. Biochem. (1992) 48:401–410.
   PubMed Web of Science ®Google Scholar
• TODD PA, FITTON A: Gallium nitrate. A review of itspharmacological properties and therapeutic potential in cancer related hypercalcaemia. Drugs (1991) 42:261–273.
   Google Scholar
• MATKOVIC V, APSELOFF G, SHEPARD DR, GERBER N: Useof gallium to treat Paget's disease of bone: a pilot study. Lancet (1990) 335:72–75.
   PubMedGoogle Scholar
• WARREL RP, JR.: Gallium nitrate for the treatment ofbone metastases. Cancer (1997) 80:1680–1685.
   PubMedGoogle Scholar
• SCHLESINGER PH, TEITELBAUM SL, PACIFICI R, BLAIRHC: A new class of antiosteoporotic agents: group Ma transition metal complexes with very high bone affin-ity and specific osteoclast inhibition properties. Bone (1998) 23 (Suppl.):S157.
   Google Scholar
• •Inhibition of osteoclast V-ATPase and bone resorption by in-dium and thallium chelates with EDTA.
   Google Scholar
• UKURA M, SHINOZUKA K, ZON G et al.: Phos-phorothioate analogs of oligodeoxynucleotides: in-hibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. ScL USA (1987) 84:7706–7710.
   PubMedGoogle Scholar
• AGRAWAL S, GOODCHILD J, CIVEIRA MP et al.: Oligode-oxynucleoside phosphoramidates and phos-phorothioates as inhibitors of human immunodeficiency virus. Proc. Natl. Acad. ScL USA (1988) 85:7079–7083.
   PubMed Web of Science ®Google Scholar